About

Cardium Therapeutics, Inc. (Cardium) is a medical technology development-stage company. The Company is primarily focused on the development, manufacture and sale of therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium owns a portfolio of biologic growth factors and related delivery... (more)

Overall

Beta: --
Market Cap (Mil.): 35.32
Shares Outstanding (Mil.): 55.18
Annual Dividend: 0.00
Yield (%): NA

Financials

  42C.BE Industry Sector
P/E (TTM): -- 1.96 3.76
EPS (TTM): -9.08 -- --
ROI: -- 0.92 2.30
ROE: -- 1.27 2.82
view overview for:

Latest News about 42C.BE

Cardium Therapeutics files $50 mln mixed shelf

WASHINGTON, Dec 7 (Reuters) - Cardium Therapeutics Inc said on Friday it may periodically sell up to $50 million in common and preferred stock, warrants, debt securities and units.

07 Dec 2007

Cardium Therapeutics Q3 results

CARDIUM THERAPEUTICS INC : * Third quarter loss per share $0.15 * Third quarter revenue $364,000 * Reuters Estimates third quarter earnings per share view $-0.17, revenue view $0.28 million

15 Nov 2007

Cardium Therapeutics files for $50 mln stock shelf

WASHINGTON, Aug 15 (Reuters) - Cardium Therapeutics Inc. filed with regulators on Wednesday to periodically sell up to $50 million in common stock.

15 Aug 2007

Cardium files $50 mln shelf offering

Aug 15 (Reuters) - Cardium Therapeutics Inc. said it filed a shelf registration statement with U.S regulators to periodically sell up to $50 million of its common stock in one or more registered direct offerings. (Reporting by Neetha Mahadevan in Bangalore)

15 Aug 2007
» More 42C.BE News

Competitors

  Price Change
CardioVascular BioTherapeutics, Inc. (CVBT.PK) $0.17 -0.00
Alsius Corporation (ALUS.PK) $0.04 0.00
ZOLL Medical Corporation (ZOLL.OQ) $26.54 +0.13

  Earnings  vs    Estimates

view overview for: